These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 33772673

  • 1. 2-(2-Benzofuranyl)-2-Imidazoline Attenuates the Disruption of the Blood-Brain Barrier in EAE via NMDAR.
    Xia N, Hua Y, Li J, Chen Y, Li X, Lin J, Xu H, Xie C, Wang X.
    Neurochem Res; 2021 Jul; 46(7):1674-1685. PubMed ID: 33772673
    [Abstract] [Full Text] [Related]

  • 2. 2-BFI attenuates experimental autoimmune encephalomyelitis-induced spinal cord injury with enhanced B-CK, CaATPase, but reduced calpain activity.
    Wang P, Wang ZW, Lin FH, Han Z, Hou ST, Zheng RY.
    Biochem Biophys Res Commun; 2011 Mar 04; 406(1):152-7. PubMed ID: 21303658
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Brain protection conferred by long-term administration of 2-(2-benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis.
    Zhu YB, Xia NG, Zhang YT, Wang XS, Liang SS, Yin WY, Xu HQ, Hou ST, Zheng RY.
    Neurochem Res; 2015 Mar 04; 40(3):572-8. PubMed ID: 25522738
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 2-BFI ameliorates EAE-induced mouse spinal cord damage: effective therapeutic time window and possible mechanisms.
    Li F, Zhang ZX, Liu YF, Xu HQ, Hou ST, Zheng RY.
    Brain Res; 2012 Nov 05; 1483():13-9. PubMed ID: 22985669
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE.
    Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, McQuaid S.
    J Neuroimmunol; 2010 Dec 15; 229(1-2):180-91. PubMed ID: 20832870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RhoA/ROCK-2 Pathway Inhibition and Tight Junction Protein Upregulation by Catalpol Suppresses Lipopolysaccaride-Induced Disruption of Blood-Brain Barrier Permeability.
    Feng S, Zou L, Wang H, He R, Liu K, Zhu H.
    Molecules; 2018 Sep 17; 23(9):. PubMed ID: 30227623
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine.
    Paul C, Bolton C.
    J Pharmacol Exp Ther; 2002 Jul 17; 302(1):50-7. PubMed ID: 12065699
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway in Brain Ischemia.
    Sun M, Shinoda Y, Fukunaga K.
    Neuroscience; 2019 Feb 10; 399():89-102. PubMed ID: 30579831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.